Affiliation:
1. Shanghai Jiao Tong University School of Medicine
2. Nanjing University of Chinese Medicine
3. Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital
4. Tongji University School of Medicine
Abstract
Abstract
Chronic non-healing wounds, an important complication of diabetes, are associated with increased mortality in patients afflicted with this disease. Excessive accumulation of M1 macrophages in diabetic wounds promotes inflammation and results in dysregulated tissue repair. Adipose tissue macrophages (ATMs) derived from healthy lean donors have the abilities to improve glucose tolerance and insulin sensitivity, and modulate inflammation. MiRNAs (miRs), which can be packaged into exosomes (Exos) and secreted from cells, serve as essential regulators of macrophage polarization. Here, we reveal that adipose tissue macrophages (ATMs) isolated from lean mice secrete miR-containing Exos, which modulate macrophage polarization and promote rapid diabetic wound healing when administered to diabetes-prone db/db mice. MiRs sequence of tissue samples from wounds treated with Exos secreted by lean ATMs (ATM-Exos) revealed that miR-222-3p was upregulated. Further analyses showed that inhibition of miR-222-3p using miR inhibitor impaired the macrophage-reprogramming effect of lean ATM-Exos. In the excisional skin wound mouse model, locally inhibiting miR-222-3p disrupted healing dynamics and failed to modulate macrophage polarization. Mechanistic studies revealed a link between miR-222-3p; Bcl2l11/Bim, an inflammatory response effector; macrophage polarization; and diabetic wound healing. In summary, lean ATM-Exos act as positive regulators of macrophage polarization by regulating miR levels in wounds and accelerating wound healing and thus have important implications for wound management in diabetes.
Publisher
Research Square Platform LLC
Reference47 articles.
1. 1. Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019. Lancet Diabetes Endocrinol 2022, 10:177–192.
2. 2. Moucheraud C, Lenz C, Latkovic M, Wirtz VJ: The costs of diabetes treatment in low- and middle-income countries: a systematic review. BMJ Glob Health 2019, 4:e001258.
3. 3. Brem H, Tomic-Canic M: Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007, 117:1219–1222.
4. 4. Sancar G, Liu S, Gasser E, Alvarez JG, Moutos C, Kim K, van Zutphen T, Wang Y, Huddy TF, Ross B, et al: FGF1 and insulin control lipolysis by convergent pathways. Cell Metab 2022, 34:171–183.e176.
5. 5. Kong M, Xie K, Lv M, Li J, Yao J, Yan K, Wu X, Xu Y, Ye D: Anti-inflammatory phytochemicals for the treatment of diabetes and its complications: Lessons learned and future promise. Biomed Pharmacother 2021, 133:110975.